E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.
Ghayas C. Issa,Jabra Zarka,Jabra Zarka,Koji Sasaki,Wei Qiao,Daewoo Pak,Daewoo Pak,Jing Ning,Nicholas J. Short,Fadi Haddad,Zhenya Tang,Keyur P. Patel,Branko Cuglievan,Naval Daver,Courtney D. DiNardo,Elias Jabbour,Tapan M. Kadia,Gautam Borthakur,Guillermo Garcia-Manero,Marina Konopleva,Michael Andreeff,Hagop M. Kantarjian,Farhad Ravandi +22 more
TL;DR: In this paper, the authors identified 172 adult patients with acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene (KMT2Ar) and compared them to 522 age-matched patients with diploid AML.
Journal ArticleDOI
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Koji Sasaki,Hagop M. Kantarjian,Susan O'Brien,Susan O'Brien,Farhad Ravandi,Marina Konopleva,Gautam Borthakur,Guillermo Garcia-Manero,William G. Wierda,Naval Daver,Alessandra Ferrajoli,Koichi Takahashi,Preetesh Jain,Mary Beth Rios,Sherry Pierce,Elias Jabbour,Jorge E. Cortes +16 more
TL;DR: The results suggest that relative incidence of overall second malignancies in CML is slightly higher than that of the general population, with minimal increase in the excess absolute risk.
Journal ArticleDOI
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
Yasmin Abaza,Hagop M. Kantarjian,Yasmin Alwash,Gautam Borthakur,Richard E. Champlin,Tapan M. Kadia,Guillermo Garcia-Manero,Naval Daver,Farhad Ravandi,Srdan Verstovsek,Jan A. Burger,Zeev Estrov,Maro Ohanian,Miranda Lim,Naveen Pemmaraju,Elias Jabbour,Jorge E. Cortes,Jorge E. Cortes +17 more
TL;DR: Decitabine plus dasatinib is a safe and active regimen in advanced CML and further studies using this combination are warranted.
Journal ArticleDOI
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia
Kapil Saxena,Shelley M. Herbrich,Naveen Pemmaraju,Tapan M. Kadia,Courtney D. DiNardo,Gautam Borthakur,Sherry Pierce,Elias Jabbour,Sa A. Wang,Carlos E. Bueso-Ramos,Sanam Loghavi,Guillin Tang,Cora M. Cheung,Lynette Alexander,Steven M. Kornblau,Michael Andreeff,Guillermo Garcia-Manero,Farhad Ravandi,Marina Konopleva,Naval Daver +19 more
TL;DR: In this paper, the authors conducted a phase 1b/2 clinical trial to assess the safety and efficacy of azacitidine with avelumab in patients with relapsed/refractory acute myeloid leukemia.
Journal ArticleDOI
Effectiveness of Homoharringtonine (Omacetaxine Mepesuccinate) for Treatment of Acute Myeloid Leukemia: A Meta-Analysis of Chinese Studies
Hagop M. Kantarjian,Susan O'Brien,Elias Jabbour,Gisoo Barnes,Ashutosh K. Pathak,Jorge E. Cortes +5 more
TL;DR: Higher overall CR rates for HHT-containing regimens in AML treatment in the Chinese studies suggest that HHT could be an active agent in the management of AML.